Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
AstraZeneca
Study ID
NCT00908271
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - 45 Years
Healthy Volunteers
Accepted

Interventions

  • Dapagliflozin — DRUG
    Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day

Study Details

The purpose of this study is to estimate the absolute oral bioavailability of dapagliflozin.

Key Dates

Start date
Jul 31, 2009
Status verified
Oct 2016
Primary completion
Aug 31, 2009
Completion
Aug 31, 2009

Study Design

Enrollment
7 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP

Arms

  • Other: Dapagliflozin
    PO and IV

Primary Outcome Measure

Absolute oral bioavailability [ Time Frame: Within the 3 days after study drug administration ]

Locations (1)

FacilityCityStateZIPSite coordinators
Covance Clinical Research Unit, Inc.MadisonWisconsin53704-

Find similar trials in Madison, WI

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Covance Clinical Research Unit, Inc.· Madison, WI

Related Studies